Company news
Dogwood Therapeutics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 18, 2024
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 16, 2024
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 8, 2024
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
May 1, 2024
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
March 25, 2024
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
February 27, 2024
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
January 21, 2024
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
January 1, 2024
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 12, 2023
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
November 5, 2023
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023
October 11, 2023
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement
September 17, 2023
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
September 11, 2023
Virios Therapeutics Announces Halt to At-The-Market Offering Sales
August 13, 2023
Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 9, 2023
Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia
August 8, 2023
Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
August 2, 2023
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study
July 16, 2023
Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia
May 14, 2023
Virios Therapeutics Announces First Quarter 2023 Financial Results
May 10, 2023
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
May 3, 2023
Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia
April 23, 2023
Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
March 13, 2023
Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023
March 6, 2023
Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023
February 12, 2023
Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program
January 4, 2023
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase
November 28, 2022
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 13, 2022
Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022
November 2, 2022
Virios Therapeutics, Inc. Announces Closing of Public Offering
September 21, 2022
Virios Therapeutics, Inc. Announces Proposed Public Offering
September 18, 2022
Virios Therapeutics, Inc. Announces Pricing of Public Offering
September 18, 2022
Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia
September 18, 2022
Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial
August 14, 2022
Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 10, 2022
Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference
August 9, 2022
Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022
August 3, 2022
Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment
July 25, 2022
Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022
Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022
May 4, 2022
Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b “FORTRESS” Clinical Trial for Fibromyalgia
April 27, 2022
Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 16, 2022
Virios Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 17, 2022
March 9, 2022
Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022
March 7, 2022
Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVID
February 27, 2022
Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference
January 3, 2022
Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia
November 30, 2021
Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 10, 2021
Virios Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Thursday, November 11, 2021
November 3, 2021
Calls
The 5 newest of 12 calls. Every call is listed under its year.
- Virios Therapeutics, Inc. (VIRI) Q2 2024 Earnings Call
Aug 7, 2024
Transcript - Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call
May 9, 2024
Transcript - Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call
Nov 13, 2023
Transcript - Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call
Aug 10, 2023
Transcript - Virios Therapeutics, Inc. (VIRI) Q3 2022 Earnings Call
Nov 14, 2022
Transcript
Decks
The 5 newest of 16 decks. Every deck is listed under its year.
- Corporate Update (September 2026)
Corporate update · 34 slides · September 2026
- Corporate Update (October 2025)
Corporate update · 32 slides · Oct 9, 2025
- Corporate Update (September 2025)
Corporate update · 16 slides · Sep 29, 2025
- Investor Presentation (February 2025)
Investor deck · 24 slides · February 2025
- Investor Presentation (January 2025)
Investor deck · 18 slides · January 2025